The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study.
 
Vincenzo Di Noia
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; MSD Oncology
 
Ettore D'Argento
No Relationships to Disclose
 
Sara Pilotto
No Relationships to Disclose
 
Carmine Carbone
No Relationships to Disclose
 
Emanuele Vita
No Relationships to Disclose
 
Giovanni Luca Ceresoli
Honoraria - AstraZeneca; Novartis; Novocure
Speakers' Bureau - Novartis; Novocure
Travel, Accommodations, Expenses - Ipsen; Roche; Sanofi
 
Giordano D. Beretta
Consulting or Advisory Role - Lilly
Speakers' Bureau - Clovis Oncology
Research Funding - Lilly (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Celgene; Ipsen; Roche; Sanofi; SERVIER
 
Giampaolo Tortora
No Relationships to Disclose
 
Emilio Bria
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche